TY - JOUR
T1 - Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina
AU - Kramerov, Andrei A.
AU - Saghizadeh, Mehrnoosh
AU - Pan, Hao
AU - Kabosova, Andrea
AU - Montenarh, Mathias
AU - Ahmed, Khalil
AU - Penn, John S.
AU - Chan, Candy K.
AU - Hinton, David R.
AU - Grant, Maria B.
AU - Ljubimov, Alexander V.
N1 - Funding Information:
Supported by the Skirball Program in Molecular Ophthalmology; seed grants from the Department of Surgery, Cedars-Sinai Medical Center; and the National Institutes of Health (grant 2R01 EY7709).
PY - 2006/5
Y1 - 2006/5
N2 - We previously documented protein kinase CK2 involvement in retinal neovascularization. Here we describe retinal CK2 expression and combined effects of CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced retinopathy (OIR). CK2 expression in human and rodent retinas with and without retinopathy and in astrocytic and endothelial cultures was examined by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction. A combination of CK2 inhibitors, emodin or 4,5,6,7-tetrabromo-benzotriazole, with octreotide was injected intraperitoneally from postnatal (P) day P11 to P17 to block mouse OIR. All CK2 subunits (α, α′, β) were expressed in retina, and a novel CK2α splice variant was detected by reverse transcriptase-polymerase chain reaction. CK2 antibodies primarily reacted with retinal astrocytes, and staining was increased around new intraretinal vessels in mouse OIR and rat retinopathy of prematurity, whereas preretinal vessels were negative. Cultured astrocytes showed increased perinuclear CK2 staining compared to endothelial cells. In the OIR model, CK2 mRNA expression increased modestly on P13 but not on P17. Octreotide combined with emodin or 4,5,6,7-tetrabromobenzotriazole blocked mouse retinal neovascularization more efficiently than either compound alone. Based on its retinal localization, CK2 may be considered a new immunohistochemical astrocytic marker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proliferative retinopathies.
AB - We previously documented protein kinase CK2 involvement in retinal neovascularization. Here we describe retinal CK2 expression and combined effects of CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced retinopathy (OIR). CK2 expression in human and rodent retinas with and without retinopathy and in astrocytic and endothelial cultures was examined by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction. A combination of CK2 inhibitors, emodin or 4,5,6,7-tetrabromo-benzotriazole, with octreotide was injected intraperitoneally from postnatal (P) day P11 to P17 to block mouse OIR. All CK2 subunits (α, α′, β) were expressed in retina, and a novel CK2α splice variant was detected by reverse transcriptase-polymerase chain reaction. CK2 antibodies primarily reacted with retinal astrocytes, and staining was increased around new intraretinal vessels in mouse OIR and rat retinopathy of prematurity, whereas preretinal vessels were negative. Cultured astrocytes showed increased perinuclear CK2 staining compared to endothelial cells. In the OIR model, CK2 mRNA expression increased modestly on P13 but not on P17. Octreotide combined with emodin or 4,5,6,7-tetrabromobenzotriazole blocked mouse retinal neovascularization more efficiently than either compound alone. Based on its retinal localization, CK2 may be considered a new immunohistochemical astrocytic marker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proliferative retinopathies.
UR - http://www.scopus.com/inward/record.url?scp=33646508546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646508546&partnerID=8YFLogxK
U2 - 10.2353/ajpath.2006.050533
DO - 10.2353/ajpath.2006.050533
M3 - Article
C2 - 16651637
AN - SCOPUS:33646508546
SN - 0002-9440
VL - 168
SP - 1722
EP - 1736
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 5
ER -